Prior to their acquisition by Cosmo Pharmaceuticals, BioXell was a research and development biopharmaceutical company with globally recognized leadership in Vitamin D and its in-depth understanding of the molecular basis of inflammation. The company was initially listed on the Swiss stock exchange prior to its acquisition.

Company: Bioxell
Fund: Alpinvest
Status: Realized
Team member: Harrold van Barlingen
Technology: Therapeutics